Sobi’s Doptelet Disappoints In Large New Indication
Chemotherapy Patients Did Not Benefit
Executive Summary
A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations.